Q32 Bio (QTTB) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Q32 Bio (QTTB) has outperformed Zentalis Pharmaceuticals (ZNTL) over the past year, gaining 157.4% versus a gain of 45.9%. Over five years, QTTB leads with a -92.5% price change compared with -96.5% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $248.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QTTB | ZNTL |
|---|---|---|
| Share price | $8.34 | $2.64 |
| Market cap | $248.28M | $259.04M |
| 1-day change | +3.09% | +5.18% |
| YTD return | +151.20% | +95.56% |
| 1-year return | +157.41% | +45.86% |
| 5-year return | -92.53% | -96.48% |
| P/E ratio (TTM) | 2.65 | — |
| EPS (TTM) | $3.15 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.57 | $6.95 |
| 52-week low | $1.91 | $1.21 |
| Distance from 52-week high | -64.62% | -62.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +374.82% | +177.65% |
| Average volume | 1.38M | 1.21M |
| Shares outstanding | 29.77M | 98.12M |
| Employees | 22 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed ZNTL by 111.6 percentage points over the past year.
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
QTTB vs ZNTL FAQ
Which is bigger, Q32 Bio or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $248.28M for Q32 Bio (QTTB).
Which stock has performed better over the past year, QTTB or ZNTL?
QTTB returned +157.41% over the past 12 months, compared with +45.86% for ZNTL (price return, excluding dividends). Past performance does not predict future results.
Are Q32 Bio and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.